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Abstract
Background: There is a paucity of specific data on early stages of chronic kidney disease (CKD) among Asian
Americans (AAs). The objective of this study was to examine the independent association of Asian race/ethnicity
and socio-demographic and co-morbidity factors with markers of early kidney damage, ascertained by ACR levels,
as well as kidney dysfunction, ascertained by eGFR levels in a large cross-sectional sample of AAs enrolled in the
National Health and Nutrition Examination Survey (NHANES).
Methods: Secondary data analyses of the NHANES 2011–2014 data of a nationally representative sample of 5907
participants 18 years and older, US citizens, and of Asian and White race. NHANES data included race (Asian vs. White),
as well as other socio-demographic information and comorbidities. Urine albumin-to-creatinine ratio (ACR) categories
and estimated glomerular filtration rate (eGFR) were used as indicators for CKD. Descriptive analyses using frequencies,
means (standard deviations), and chi-square tests was first conducted, then multivariable logistic regression serial
adjustment models were used to examine the associations between race/ethnicity, other socio-demographic factors
(age, sex, education), and co-morbidities (obesity, diabetes, hypertension) with elevated ACR levels (A2 & A3 – CKD
Stages 3 and 4–5, respectively) as well as reduced eGFR (G3a-G5 and G3b –G5 - CKD Stage 3–5).
Results: AAs were more likely than White participants to have ACR levels > 300mg/g (A3) (adjusted OR (aOR) (95% CI)
2.77 (1.55, 4.97), p = 0.001). In contrast, adjusted analyses demonstrated that AAs were less likely to have eGFR
levels < 60 ml/min/1.73 m2 (G3a-G5) (aOR (95% CI) 0.50 (0.35, 0.72), p < .001).
Conclusions: This is one of the first large U.S. population-based studies of AAs that has shown a comparatively higher
risk of elevated ACR > 300mg/g levels (A3) but lower risk of having eGFR levels < 60ml/min/1.732m2 (G3a-G5). The
findings support the need to address the gaps in knowledge regarding disparities in risk of early stage CKD among AAs.
Background
Asian Americans (AA)s are projected to be the second
fastest growing racial/ethnic group in the U.S and are
projected to nearly double to 9.3% of the total popula-
tion by 2060 [1]. Currently, AAs represent 5.8% of the
overall U.S. population [2] and there are approximately
20.4 million Asian adults and children living in the U.S.
[3, 4]. Furthermore based on the 2016U.S. Census, major
Asian subgroups of people reported were Chinese (except
Taiwanese) (4.9 million), Asian Indian (4.1 million), Filipino
(3.9 million), Vietnamese (2.1 million), Korean (1.8 million),
and Japanese (1.5 million).
Thirty million adults in the United States (US) have
chronic kidney disease (CKD) [5]. Compared to Whites,
the prevalence of end-stage renal disease is 1.5 times
greater for AAs [6]. AAs constitute about 5.5% of all pa-
tients in the U.S. receiving dialysis [7] and 5% of patients
living with a functioning kidney transplant in 2013 [8].
In 2011, total Medicare spending rose 5% to $549.1 bil-
lion, while end-stage-renal disease expenditures rose 5.4%
to $34.3 billion. In addition, total fee-for-service Medicare
expenditures per person per year were $87,945 in 2011
[9]. The costs and spending will continue to increase
based on the projected population growth of AAs in the
U.S. in the next 50 years. Given these projections, disease
prevention are imperative to address in the early stages of
CKD among this population. While state-level data exists
on end-stage renal disease and its treatment, there are no
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granular and precise data on early stages of CKD specific-
ally among AAs.
CKD is common in people with cardiovascular disease
(CVD), diabetes mellitus (DM), hypertension (HTN),
and obesity [10]. DM and HTN are the two major risk
factors for CKD worldwide [11] and are listed as the pri-
mary causes for 70% of new cases of CKD in the U.S.
[12]. The prevalence of DM is approximately 40% higher
in AAs relative to Whites [12] and 19% of AAs have
HTN [13, 14]. Obesity is disproportionately more preva-
lent in certain Asian subgroups, is also associated with
increased risk of development of CKD [15–17] as well as
various kidney disease risk factors (e.g., HTN, DM, and
dyslipidemia) [18].
There is a paucity of studies exploring the association of
albumin to creatinine ratio (ACR) and estimated glomuer-
ular filtration rate (eGFR) with CKD among AAs. Inter-
national researchers who studied ACR and eGFR with
CKD among Asians were from countries such as China,
Korea, Japan, and Thailand. Among Asian populations with
DM, CKD progresses twice as rapidly [19]. HTN has been
associated with CKD among Chinese, Japanese, Filipino, and
South Asians [14, 20, 21]. International researchers also
found that obesity led to CKD through both indirect (i.e.,
DM, HTN, dyslipidemia) and direct mechanisms (i.e., glom-
erular hyperfiltration, inflammation) [22, 23].
Jolly et al. [24] and Mau et al. [25] utilized the U.S.
National Kidney Foundation (NKF) Kidney Early Evalu-
ation Program (KEEP) cross-sectional data of community-
dwelling racial/ethnic participants and found AAs to have
one of the highest odds for CKD based ACR levels.
Kataoka-Yahiro et al. [26] and Wong et al. [27] conducted
a cross-sectional study of the National Kidney Foundation
of Hawaii (NKFH) Kidney Early Screening Program
(KEDS) of community dwelling participants to further
examine the relationship of risk factors and CKD of Asian
Pacific Islanders (Native Hawaiians, Japanese, Chinese,
Filipino, and Whites) in Hawaii. ACR and/or urine albu-
min levels, respectively were used as predictors for CKD.
Significant results related to ACR in these studies included
BMI, glucose, HTN, and Asian and/or Pacific Islander
race/ethnicity.
Racial/ethnic differences in ACR and eGFR evaluation
and CKD definition and staging among AAs is particularly
needed in the early stages of CKD [28, 29]. While impaired
ACR and eGFR have been associated with heightened risk
of cardiovascular complications and mortality among
Asians [30], further research is needed to determine the
impact of ACR and eGFR markers of kidney damage and
kidney function, respectively, in AA populations.
Hence, identification of CKD in its earlier stages is a
high priority in the AA population [27]. Thus, to better
inform the field, we sought to examine the relationship
between Asian race/ethnicity and CKD indicators among
a nationally representative cohort of AA adults. We exam-
ined the independent association of Asian race/ethnicity
and socio-demographic and co-morbidity factors with
markers of early kidney damage, ascertained by higher
ACR levels, as well as kidney dysfunction, ascertained by
lower eGFR levels. We further examined the association
between socio-demographic and co-morbidity factors with
these outcomes stratified by race/ethnicity.
Methods
Study design and population
In this study, we examined data from participants enrolled
in the National Health and Nutrition Examination Survey
(NHANES) [31] over the period of 2011–2014. NHANES
is a national population-based survey, designed to assess
the health and nutritional status of adults and children in
the U.S. The survey is unique in that it combines inter-
views, physical examinations and laboratory data. In the
NHANES study, survey data is obtained via personal
household interviews of a stratified, multistage probability
sample of the civilian, non-institutionalized population of
the U.S. Data from the NHANES were de-identified and
provided as downloadable public-use data files.
Participants included were 18 years and older and of
AA or non-Hispanic White race/ethnicity. Participants
were excluded if they were pregnant women, if their race
was Mexican-American or other Hispanic categories,
non-Hispanic Black, if they were multi-racial, if they did
not identify their race/ethnicity, and if their sampling
weights were missing or zero. After the exclusions, the sam-
ple included 5907 non-Hispanic Asian and non-Hispanic
White participants (referred to in the remainder of the study
as Asian and White participants, respectively).
Measurements and definitions
The primary predictor of interest was race/ethnicity,
which was categorized in analyses as Asian and White.
In the NHANES study, race/ethnicity information was
self-reported by participants. Other predictors included
were age, sex, education (measured for SES), DM, HTN,
and BMI.
The primary outcomes of interest were ACR and eGFR
[9]. ACR was analyzed at two cutpoints: (1) ≥ 30 mg/g
(Kidney Disease Improving Global Outcomes [KDIGO]
category A2 – CKD Stage 3), and (2) > 300mg/g (KDIGO
category A3 – CKD Stages 4 & 5) [32]. ACR was calcu-
lated as urine albumin (mg/dL) divided by urine creatinine
(g/dL ratio). In the NHANES study, ACR specimens
(urine albumin and urine creatinine) were measured in a
random urine collection by the Mobile Examination Cen-
ter (MEC) (first collection) and a first morning void urine
collected by the participant at home (second collection).
eGFR was examined at two thresholds chosen as (1) < 60
ml/min/1.73m2 (KDIGO category G3a – G5 - Stages 3–5),
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and (2) < 45ml/min/1.73m2 (KDIGO category G3b –G5 -
Stage 3–5). We specifically selected these cut-points as
indicators of moderate vs. severe CKD, respectively. The
eGFR was calculated using the Chronic Kidney Disease
Epidemiology Collaboration equation: eGFR = 141 x min
(Scr/k,1)
α x max (Scr/k,1)
-1.209 × 0.993Age × 1.018 [if fe-
male], where, Scr is serum creatinine in mg/dl, k is 0.7 for
females and 0.9 for males, α is − 0.329 for females and
− 0.411 for males, min indicates the minimum of Scr/k or 1,
and max indicates maximum of Scr/k or 1 [33].
Statistical analyses
Descriptive statistics for the survey data were summarized
by frequencies and percentages for categorical variables,
and by means and standard deviations or medians and
interquartile ranges for continuous variables, depending
on the distributions. Bivariate analyses used Rao-Scott
chi-square tests to assess associations between the out-
comes ACR and eGFR and other factors.
Multivariable logistic regression analyses were used to
examine the association between race/ethnicity, other
socio-demographic factors, and comorbidities with ele-
vated ACR, and reduced eGFR, based upon the chosen
cut points. The analyses accounted for confounding by
age (categorized as 18–64, 65–74, 75 and older years),
education (≤ high school/GED, some college, college
graduate), sex (male, female), BMI (categorized as nor-
mal [< 25.0 kg/m2], overweight [25.0–29.9 kg/m2] and
obesity [≥30.0 kg/m2]), and presence of self-reported
DM (yes or no) and HTN (yes or no). In secondary ana-
lyses, logistic regression models were fit stratified by race/
ethnicity using the cut-points for ACR ≥30mg/g and
> 300mg/g and for eGFR < 60 and < 45ml/min/1.73m2.
Results are presented as odds ratios (ORs) with 95% confi-
dence intervals (CIs).
All analyses accounted for the NHANES’s complex
multistage sampling design in order to ensure that cal-
culated estimates were representative of the U.S. civilian
non-institutionalized population. A value of p < 0.05 was
considered statistically significant. Statistical analyses
were conducted using SAS software, version 9.4 [34].
Figures were generated using R version 3.0.2.
Results
Study population
After applying the eligibility criteria, the final study
population comprised 5907 Asian and White partici-
pants. The total sample size for the ACR analyses was
5792 (115 participants were missing ACR data), and
5605 for the eGFR analyses (302 participants were miss-
ing eGFR data). Table 1 provides participants’ descriptive
characteristics stratified by race/ethnicity. Asians were
more likely than Whites to be 18–64 years of age (86%
vs. 79%), college graduates (49.9% vs. 34.4%), have
normal weight (60% vs. 31%) and less frequently had
HTN (22% vs 34%). Descriptive statistics by race/ethni-
city for the outcomes, ACR and eGFR are summarized
in Table 2. Asians had higher mean and median levels of
ACR than Whites when compared for ACR overall and
when examined at A2 and A3 (CKD Stages 3 and 4–5,
respectively), ACR levels were skewed towards high
values rendering means much higher than medians; thus
the median comparisons may be preferable. eGFR levels
were reasonably normally distributed and means and
medians were similar. Asians has a higher mean overall
but the Asian and White means were comparable at
levels of G3a–G5 and G3b-G5 (CKD Stage 3–5).
Comparison of Asians and whites in serially-adjusted,
multivariable logistic regression models for ACR ≥ 30mg/g
and ACR > 300mg/g (A2 and A3) and eGFR < 60ml/min/
1.73m2 and eGFR < 45ml/min/1.73m2 (G3a-G5 and G3b-G5)
The ACR levels of Asians and Whites were compared
using four models of serial adjustments: unadjusted; age-
and sex-adjusted; age-, sex- and education adjusted, includ-
ing education as a measure of socioeconomic status; and a
model with additional adjustment for health characteristics
Table 1 Characteristics of the study participants by race/ethnicity
Characteristics Overall
(n = 5907)
Race (%) Weighted
p-valueAsian
(n = 1443)
White
(n = 4464)
Age Group (years) < 0.001
18–64 79 86 79
65–74 12 10 12
75 and older 9 4 9
Education Group < 0.001
≤ High School/GED 30.8 26.6 31.1
Some College 33.7 23.4 34.5
College Graduate 35.5 49.9 34.4
Sex 0.13
Male 49 47 49
Female 51 53 51
Body Mass Index (kg/m2) < 0.001
Normal 34 60 31
Overweight 33 28 34
Obese 33 12 35
Have Hypertension < 0.001
Yes 34 22 34
No 66 78 66
Have Diabetes 0.92
Yes 11 11 11
No 89 89 89
Weighted column percentage. Analyses conducted using chi-square tests
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(normal, overweight, obesity, DM, and HTN). For ACR
levels ≥30mg/g differences were not significant in the
unadjusted model, but with age-, sex-adjustment and with
further adjustment, Asians had increasing odds of higher
ACR levels than Whites at 1.35 (95% CI = 1.05, 1.74,
weighted p-value = 0.020) (Table 3; Fig. 1). Significant
socio-demographic and co-morbidity factors were (a) age
65–74 and 75 and older with odds ratios of 1.39 and 3.19,
(95% CI = 1.02, 1.89; 2.43, 4.17), respectively; (b) BMI over-
weight with an odds ratio of − 0.65 (95% CI = 0.49, 0.88);
(c) DM with an odds ratio of 2.89 (95% CI = 2.20, 3.79); and
(d) HTN with an odds ratio of 1.77 (95% CI = 1.38, 2.27).
Using ACR of > 300 mg/g, Asians had significantly
higher odds in all of the serial-adjusted models reaching
an odds ratio of 2.77 in the fully adjusted model (95%
CI = 1.55, 4.97, weighted p-value = 0.001). Significant
socio-demographic and co-morbidity factors were (a)
age 75 and older with an odds ratio of 3.79 (95% CI =
1.91, 7.52); (b) DM with odds ratio of 7.68 (95% CI =
4.24, 13.92); and (c) HTN with odds ratio of 3.6 (95%
CI = 1.77, 7.29) (Table 3; Fig. 1). At the eGFR level of
< 60ml/min/1.73m2, Asians consistently had lower odds
compared to Whites in all of the serial adjusted models.
The odds ratio went from 0.38 (95% CI = 0.27–0.52,
weighted p-value = < 0.001) in the unadjusted model to
0.50 (95% CI = 0.35, 0.72, weighted p-value = < 0.001) in
the fully adjusted model (Table 4; Fig. 2). Significant
socio-demographic and co-morbidity factors were (a)
ages 65–75 and 75 and older with odds ratios of 4.99 and
17.15 (95% CI = 3.53, 7.06 and 12.45, 23.61), respectively;
(b) DM with an odds ratio of 2.21 (95% CI = 1.61, 3.03);
and (c) HTN with an odds ratio of 2.7 (95% CI = 2.02,
3.61). For eGFR < 45ml/min/1.73m2, Asians had a
significantly lower odds than Whites in the unadjusted
model [odds ratio = 0.39 (95% CI = 0.22, 0.67, weighted
p-value = 0.001)] but the odds ratio increased and
became non-significant with age-, sex- adjustment, and
remained non-significant with adjustment for additional
covariates [odd ratio = 0.62 (95% CI = 0.33, 1.17, weighted
p-value = 0.139) (Table 4: Fig. 2).
Association of Other Socio-Demographic and
Comorbidities with CKD outcomes across racial/ethnic
subgroups
To better understand the risks of Asians and Whites, sep-
arate models were fit for the two ethnicities. For ACR
levels ≥30mg/g, diabetes (p = 0.001) and having hyperten-
sion (p = .022) were significant risk factors for both Asians
and Whites and only sex for Whites (p = 0.000) (Additional
file 1: Table S1). For ACR levels > 300mg/g DM was sig-
nificant risk factor for both ethnicities (p = 0.032 and 0.000,
respectively). Older age and HTN was also significant for
Whites (p = 0.000 and p = 0.002, respectively) (Additional
file 1: Table S2). For eGFR < 60ml/min/1.73m2, older age
(p = 0.000), DM (p = 0.001 and 0.000, respectively), and
having HTN (p = 0.003 and 0.000), were significant risk
factors for Asians and for Whites (Additional file 1: Table
S3). Results had a similar pattern using eGFR < 45ml/min/
1.73m2 although statistical significance was not observed
(Additional file 1: Table S4).
Discussion
The objective of this study was to examine the relation-
ship of Asian race/ethnicity, socio-demographic and
Table 2 Mean and median urine albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) by race
Race
Outcome Statistic Asians White
ACR mg/g (A1, A2, A3) Mean ± SE 38.4 ± 7.1 25.7 ± 2.6
[CKD Stage 1–5] Median (Q1, Q3) 7.2 (4.8, 12.8) 6.8 (4.6, 12.1)
ACR≥ 30mg/g (A2) Mean ± SE 311.4 ± 68.1 201.4 ± 27.0
[CKD Stage 3] Median (Q1, Q3) 76.6 (39.8, 198.1) 57.4 (39.6, 120.8)
ACR > 300mg/g (A3) Mean ± SE 1255.7 ± 298 1225.1 ± 204
[CKD Stages 4–5] Median (Q1, Q3) 628.2 (427.0, 1081.6) 657.1 (404.9, 1140.9)
eGFR ml/min/1.73 m2 (G1 to G5) Mean ± SE 101.2 ± 0.5 90.3 ± 0.3
[CKD Stages 1–5] Median (Q1,Q3) 103.3 (90.2, 115.5) 91.8 (76.8, 105.5)
eGFR < 60 ml/min/1.73 m2 (G3a-G5) Mean ± SE 48.6 ± 1.63 47.7 ± 0.57
[CKD Stage 3 to 5] Median (Q1, Q3) 51.8 (43.9, 57.5) 50.7 (41.9, 55.7)
eGFR < 45 ml/min/1.73 m2 (G3b-G5) Mean ± SE 34.1 ± 2.8 33.5 ± 0.9
[CKD Stage 3 to 5] Median (Q1, Q3) 37.1 (27.9, 42.6) 35.7 (30.6, 41.0)
SE standard error; Q1 1st quartile, Q3 3rd quartile
Note: UACR has a skewed distribution and therefore we would suggest using median (Q1, Q3), while eGFR is normally distributed and therefore would suggest
using mean and standard error
ACR ≥ 30 mg/g (A2) – Moderately increased; ACR > 300 mg/g (A3) – Severely increased; eGFR < 60ml/min/1.73 m2 (G3a) – Mildly to moderately decreased; eGFR
< 45ml/min/1.73 m2 (G3b) – Moderately to severely decreased
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Fig. 1 Comparison of Asians & Whites in Multivariable Logistic Regression Models Adjusted for ACR ≥30 mg/g (A2) and ACR > 300mg/g (A3)
Table 3 Comparison of Asians and Whites in serially-adjusted, multivariable logistic regression models for ACR ≥ 30 mg/g (A2) and
ACR > 300mg/g (A3)
ACR≥ 30 mg/g (A2) ACR > 300mg/g (A3)
Regression Model Comparisons Odds Ratio (95% CI) Weighted p-value Odds Ratio (95% CI) Weighted p-value
Model 1 Asian vs White 1.12 (0.9, 1.39) 0.301 2.06 (1.25, 3.39) 0.005
Model 2 Ages 65–74 vs Ages < 65 2.01 (1.5, 2.68) 0.000 1.86 (0.81, 4.28) 0.144
Ages 75 & higher vs Ages < 65 4.49 (3.52, 5.72) 0.000 8.54 (4.58, 15.92) 0.000
Female vs Male 1.25 (1, 1.55) 0.050 0.75 (0.42, 1.35) 0.342
Asian vs White 1.27 (1.01, 1.58) 0.040 2.62 (1.53, 4.47) 0.000
Model 3 Ages 65–74 vs Ages < 65 1.98 (1.48, 2.65) 0.000 1.83 (0.79, 4.21) 0.157
Ages 65–74 vs Ages < 65 4.26 (3.33, 5.44) 0.000 8.03 (4.39, 14.68) 0.000
Female vs Male 1.24 (0.99, 1.54) 0.059 0.74 (0.41, 1.34) 0.322
Some College vs < HS/GED 0.86 (0.67, 1.11) 0.252 0.77 (0.41, 1.45) 0.416
College Graduate vs < HS/GED 0.65 (0.49, 0.85) 0.002 0.64 (0.31, 1.29) 0.211
Asian vs White 1.32 (1.05, 1.66) 0.017 2.7 (1.55, 4.7) 0.000
Model 4 Ages 65–74 vs Ages < 65 1.39 (1.02, 1.89) 0.038 0.78 (0.33, 1.83) 0.563
Ages 75 & higher vs Ages < 65 3.19 (2.43, 4.17) 0.000 3.79 (1.91, 7.52) 0.000
Female vs Male 1.23 (0.98, 1.55) 0.072 0.79 (0.42, 1.5) 0.473
Some College vs < HS/GED 0.88 (0.68, 1.14) 0.328 0.76 (0.4, 1.44) 0.400
College Graduate vs < HS/GED 0.76 (0.57, 1) 0.051 0.86 (0.4, 1.83) 0.694
BMI (Overweight vs Normal) 0.65 (0.49, 0.88) 0.005 0.86 (0.42, 1.76) 0.673
BMI (Obese vs Normal) 1.02 (0.77, 1.36) 0.870 0.84 (0.45, 1.58) 0.595
Diabetes (Yes vs No) 2.89 (2.2, 3.79) 0.000 7.68 (4.24, 13.92) 0.000
Hypertension (Yes vs No) 1.77 (1.38, 2.27) 0.000 3.6 (1.77, 7.29) 0.000
Asian vs White 1.35 (1.05, 1.74) 0.020 2.77 (1.55, 4.97) 0.001
CI confidence interval, BMI body mass index, < HS/GED less than high school or GED equivalent
ACR ≥ 30 mg/g (A2) – Moderately increased; ACR > 300 mg/g (A3) – Severely increased
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Table 4 Comparison of Asians and Whites in serially-adjusted, multivariable logistic regression models for eGFR < 60 ml/min/1.73m2
(G3a-G5) and eGFR < 45 ml/min/1.73m2 (G3b-G5)
eGFR < 60 ml/min/1.73m2 eGFR < 45 ml/min/1.73m2
Regression Model Comparisons Odds Ratio (95% CI) Weighted p-value Odds Ratio (95% CI) Weighted p-value
Model 1 Asian vs White 0.38 (0.27, 0.52) 0.000 0.39 (0.22, 0.67) 0.001
Ages 65–74 vs Ages < 65 7.40 (5.3, 10.32) 0.000 9.64 (5.03, 18.5) 0.000
Model 2 Ages 75 & higher vs Ages < 65 25.41 (18.83, 34.27) 0.000 45.26 (25.46, 80.44) 0.000
Female vs Male 1.25 (0.97, 1.61) 0.082 1.48 (1.02, 2.13) 0.037
Asian vs White 0.50 (0.35, 0.7) 0.000 0.61 (0.34, 1.09) 0.098
Model 3 Ages 65–74 vs Ages < 65 7.34 (5.26, 10.24) 0.000 9.27 (4.82, 17.85) 0.000
Ages 75 & higher vs Ages < 65 24.7 (18.33, 33.29) 0.000 40.49 (22.31, 73.47) 0.000
Female vs Male 1.23 (0.96, 1.59) 0.101 1.36 (0.94, 1.98) 0.101
Some College vs < HS/GED 0.89 (0.67, 1.2) 0.451 0.64 (0.42, 0.98) 0.039
College Graduate vs < HS/GED 0.79 (0.58, 1.07) 0.126 0.36 (0.22, 0.6) 0.000
Asian vs White 0.50 (0.36, 0.71) 0.000 0.63 (0.35, 1.15) 0.134
Model 4 Ages 65–74 vs Ages < 65 4.99 (3.53, 7.06) 0.000 5.38 (2.66, 10.89) 0.000
Ages 75 & higher vs Ages < 65 17.15 (12.45, 23.61) 0.000 25.06 (13.8, 45.52) 0.000
Female vs Male 1.31 (1.02, 1.7) 0.038 1.47 (0.97, 2.22) 0.066
Some College vs < HS/GED 0.92 (0.68, 1.24) 0.576 0.62 (0.4, 0.97) 0.038
College Graduate vs < HS/GED 0.96 (0.7, 1.3) 0.775 0.46 (0.27, 0.77) 0.004
BMI (Overweight vs Normal) 1.13 (0.8, 1.59) 0.484 1.02 (0.61, 1.7) 0.944
BMI (Obese vs Normal) 1.08 (0.77, 1.52) 0.648 1.12 (0.66, 1.9) 0.679
Diabetes (Yes vs No) 2.21 (1.61, 3.03) 0.000 3.19 (1.99, 5.1) 0.000
Hypertension (Yes vs No) 2.7 (2.02, 3.61) 0.000 3.31 (2, 5.48) 0.000
Asian vs White 0.50 (0.35, 0.72) 0.000 0.62 (0.33, 1.17) 0.139
CI confidence interval, BMI body mass index, <HS/GED less than high school or GED equivalent
eGFR < 60ml/min/1.73 m2 (G3a-G5) – Mildly to moderately decreased; eGFR < 45ml/min/1.73 m2 (G3b-G5) – Moderately to severely decreased
Fig. 2 Comparison of Asians & Whites in Adjusted Multivariable Logistic Regression Models for eGFR < 60 mg/ml/1.73 m2 and
eGFR < 45 mg/ml/1.73 m2
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co-morbidity factors, and CKD outcomes in a nationally
representative sample of AAs and Whites who were en-
rolled in the NHANES study from 2011 to 2014. To our
knowledge, this is one of the first large U.S. population-
based studies that has shown a comparatively higher risk of
elevated ACR levels (A3), an early marker of kidney dam-
age, among Asians compared to Whites.
CKD is defined as the abnormality of kidney structure
or function, present for > 3months, with varying implica-
tions upon health status and CKD Stages 1 to 5 depending
upon underlying cause. In this study, the ACR and eGFR
levels of Asians and Whites were compared using four
models of serial adjustments for socio-demographic and
co-morbidity factors, adjusted and unadjusted. With adjust-
ment, ACR was a key determinant of CKD [35, 36]. In this
study, socio-demographic and co-morbidity factors which
were significant for KDIGO-defined A2, A3, and G3a-G5
were related to age, DM, and HTN independent of race/
ethnicity. Similarly, when race/ethnicity was stratified into
Asian and White; age, DM, and HTN were significant fac-
tors related to A2, A3, and G3a-G5. These results were
consistent with the existing literature [24–27]. Other stud-
ies also indicated that albuminuria was an important correl-
ate of HTN among patients with CKD [37, 38] as well as
an indicator of insulin resistance [39, 40]. Age was the best
correlate of low eGFR (eGFR < 60ml/min/1.73m2) while
HTN was the greatest predictor of albuminuria [41]. In this
study, obesity was a significant independent factor worth
mentioning for A2, but not for A3 or eGFR of 60ml/min/
1.73m2. There were several studies which support this study
finding [42, 43], but obesity was not a consistent finding in
this study with ACR or eGFR. In this study, albuminuria
and eGFR prevalence was independently higher among par-
ticipants who were (a) older, (b) with DM, (c) had HTN,
and (d) of Asian background. These findings suggest a need
for access to early screening and detection of kidney dam-
age in the community [24, 26, 27, 44]. More specifically,
targeted programs which include not only CKD early
screening, but also encompasses the identification of CVD
risk factors (HTN, DM, Obesity) inclusive of culturally ap-
propriate screening, detection, referral, and intervention in
routine kidney screening [24, 26].
In this study, we observed that Asian participants had
a 2.77-fold higher risk of KDIGO-defined albuminuria
categories A3 and a trend towards higher risk of cat-
egory A2. Studies of AA samples have also similar re-
sults of a trend towards higher risk of albuminuria
category A2 [24, 26, 27, 45, 46]. There is a paucity of
studies which have found a higher risk of albuminuria
category A3 among AA participants compared to their
non-Hispanic White counterparts. Possible reasons to con-
sider to explain this apparent higher risk may include diet
[47], genetic or environmental [45, 48–50], urine specimen
procedure [51, 52], and other laboratory values [53, 54]. Sato
et al. [47] analyzed 675 men and 924 women who did not
have DM and found those who had less animal protein
and more B-cryptoxanthin in the diet did not have ab-
normal microalbuminuria in comparison to those who
ingested n-3 polyunsaturated fatty acids. Sakamoto et
al. [50] found YKL-40 levels were significantly elevated
in type 1 diabetic patients than in healthy controls and
demonstrated YKL-40 levels were a determinant of ACR
independent of other risk factors. Prior et al. [55] found a
significant association between genotype (GG/GA/AA)
and urinary albumin (normoalbumuria vs. micro/macroal-
buminuria, p = 0.01). Mashima et al. [56] single nucleotide
polymorphisms (SNPs) in six proinflammatory cytokine
genes IL-6 and CCL1 genes were associated with albumin-
uria and the combination of these genotypes had an addi-
tive effect on the prevalence and severity of albuminuria.
Matsushita et al. [51] reported that measurements of
creatinine and albuminuria were not standardized. In
some studies, researchers measured creatinine and albu-
minuria using fresh samples while others used frozen
samples which may have an effect on the validity of results
for both eGFR and albuminuria. Carter et al. [52] de-
scribed the influence of urine creatinine concentrations
on the relation of albumin-creatinine ratio with cardiovas-
cular disease events from the Multi-Ethnic Study of
Athersclerosis (MESA). Carter et al. found urine creatin-
ine was lower in older female, and White and Chinese par-
ticipants, and those with lower body weight (reflecting
lower muscle mass). The urine tonicity may make spot
urine creatinine a less reliable marker of muscle mass than
24 h urine creatinine.
In this study, we utilized the CKD-EPI Creatinine
Equation based on the CKD Prognosis Consortium
(CKD-PC) [57–59]. The CKD-PC provided a compre-
hensive method to define and stage CKD, eGFR, and al-
buminuria on kidney outcomes.
In our analyses of kidney function defined by eGFR as
the outcome of interest, we observed contrasting associ-
ations, such that Asians had a lower risk of mild to mod-
erately reduced eGFR (< 60ml/min/1.73m2) compared
to Whites. There are limitations in the application of
creatinine-based GFR estimating equations. For example,
the equation ascertaining kidney function using these
methods were not specifically derived from AA popula-
tions and cannot overcome the limitations of serum cre-
atinine as a filtration marker, which may be lower in
Asian populations due to lower generation of creatinine
from muscle. Indeed, several studies have proposed
using an Asian-specific ethnic equation for the Chronic
Kidney Disease Epidemiology Collaboration formula
analysis. Hence, in our study the eGFR findings must be
carefully interpreted, and further studies are needed to
define what ethnic equation may be used for AAs. A
limitation in the use of serum creatinine to eGFR ratio
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within this study is that the ratio is different among vari-
ous Asian subgroup populations. For example, Horio et
al. [60] and Teo et al. [61] reported the correction fac-
tors of Chinese, Malay, and Indians/other (1.100, 1.032,
and 0.996 for the CKD-EPI equation, respectively). How-
ever, in the NHANES cohort, AAs were examined as a
single non-granular sub-group. Levey, Becker, and Inker
[33] have recommended for the initial assessment of
eGFR, measuring serum creatinine and reporting eGFR
be based on CKD-EPI 2009 equation. They also men-
tioned if there is difficulty to confirm the eGFR results
based on “extremes of muscle mass, diet, interference of
assay”, cystatin C should be measured and eGFR should
be measured directly using clearance procedure rather
than initial assessment of albuminuria measuring urine
albumin and creatinine based on ‘spot’ urine collection
and reporting of ACR (p.1, 5–6). Hence, further studies
are needed to determine the role of cystatin C and
cystatin-C based eGFR assessment among the AA popu-
lation and individual subgroups.
Our study has a number of strengths, including its
examination of a large nationally represent cohort of
healthy U.S. participants with a large sample of AAs;
comprehensive availability of detailed information, includ-
ing socio-demographic and comorbidity data; and rigor-
ous analytic approaches that examined various thresholds
of ACR and eGFR and accounted for key confounders of
the Asian race/ethnicity - CKD associations. However,
several limitations of our study should be acknowledged.
First, given the study’s cross-sectional and observational
nature, our findings do not confirm causal associations.
Second, as socio-demographic and comorbidity data were
self-reported by the participants, it is possible that the par-
ticipants’ responses may be affected by biases. Participants
who self-reported and self-selected to be in this study may
not be representative of the general population. This study
did not report on lab values, medications, or management
of HTN, DM, obesity, or CKD which could provide add-
itional objective information along with self-reported data.
Third, since AAs were aggregated in the NHANES cohort,
the results may not be generalizable to Asian subgroups.
Fourth, the definition of eGFR is based on single assess-
ment of serum creatinine which may introduce misclassi-
fication bias. Low muscle mass and serum creatinine and
creatinine generation in AAs may also affect the denomin-
ator in the ACR ratio, thereby falsely augmenting ACR
among this population.
Conclusions
In conclusion, our findings suggest that AAs are at higher
risk of early damage manifested by abnormal levels of albu-
minuria. It is important to continue to explore and examine
large cohorts or longitudinal studies on AAs and sub-
groups in order to accurately identify CKD prevalence
in community dwelling populations. Valid and reliable
outcome measures of ACR and eGFR are needed to
examine the relationship to socio-demographic and
co-morbidity risk factors in efforts to justify a need to
target culturally appropriate early screening, detection,
referral, and intervention in community settings.
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